Skip to main content
Midas Edge

Nuo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 19, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 19, 2024

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Special Note Regarding Forward-Looking Statements
Trademarks
PART I1
ITEM 1. Business1
ITEM 1A. Risk Factors7
ITEM 1B. Unresolved Staff Comments15
ITEM 1C. Cybersecurity15
ITEM 2. Properties15
ITEM 3. Legal Proceedings15
ITEM 4. Mine Safety Disclosures15
PART II16
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities16
ITEM 6. [Reserved]16
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations17
ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk20
ITEM 8. Financial Statements and Supplementary Data20
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure20
ITEM 9A. Controls and Procedures20
ITEM 9B. Other Information21
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections21
PART III22
ITEM 10. Directors, Executive Officers and Corporate Governance22
ITEM 11. Executive Compensation24
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters25
ITEM 13. Certain Relationships and Related Transactions, and Director Independence27
ITEM 14. Principal Accounting Fees and Services28
PART IV29
ITEM 15. Exhibits and Financial Statement Schedules29
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.